Compared side by side
BPC-157 vs Thymosin Beta-4: how they differ
The short answer
BPC-157 is a peptide derived from a protective protein in human gastric juice; in animal studies it speeds the repair of tendons, ligaments, muscle and gut lining, partly by growing new blood vessels. Thymosin beta-4 is the full-length protein TB-500 is cut from: it regulates actin, the scaffolding cells use to move, and in animal studies it speeds tissue repair and supports new blood vessel growth. BPC-157 is taken once or twice daily and full thymosin beta-4 weekly, and neither has been tested by injection for injuries in a controlled human trial.
Side by side
| Compared | BPC-157 | Thymosin Beta-4 |
|---|---|---|
| Category | Healing & recovery | Healing & recovery |
| Also known as | Body Protection Compound 157, BPC157 | Tβ4, Full TB4 |
| What it is | A peptide derived from a protective protein in your stomach. | The full-length version of the protein TB-500 is cut from. |
| How it works | Synthetic pentadecapeptide derived from a protein in human gastric juice. In animal studies it promotes angiogenesis, speeds tendon, ligament and muscle healing, modulates dopamine and serotonin systems, and protects the gut lining. | Full-length Thymosin Beta-4 (as opposed to the TB-500 fragment). In cell and animal studies it promotes tissue repair, angiogenesis and cell survival. Regulates actin dynamics and plays a role in embryonic development and wound healing. |
| Commonly reported | Faster recovery from tendon and ligament injuries, and a calmer gut. It's one of the most widely used peptides in the community; the human studies so far are three small uncontrolled pilots. | Less nagging joint and soft-tissue pain and stiffness over a few weeks, and sometimes tiredness for a day after injecting. Its human trials are small eye-drop and skin-gel studies; injected use for injuries hasn't been tested in people. |
| Studied range | Research range: 200–500 mcg. Studied in research — not a recommendation. | Research range: 2–2.5 mg. Studied in research — not a recommendation. |
| How often | Once or twice daily | Weekly |
| Half-life | ~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes) | ~0.5–2 hours (given IV to healthy volunteers) |
| Route | SubQ injection, IM injection, Oral (less studied) | SubQ injection, IM injection |
| Typical run | Typically 4–12 weeks. Many run until injury resolves then stop. Some run indefinitely at lower doses. Opinions vary widely. | Shorter cycles than TB-500 typical — 4–6 weeks. Less community data than TB-500 fragment. |
| Evidence | Emerging: primarily preclinical / limited human data | Emerging: primarily preclinical / limited human data |
| Common side effects | Nausea (rare), injection site irritation, vivid dreams, dizziness | Injection site reaction, fatigue, headache |
- Category
- BPC-157Healing & recovery
- Thymosin Beta-4Healing & recovery
- Also known as
- BPC-157Body Protection Compound 157, BPC157
- Thymosin Beta-4Tβ4, Full TB4
- What it is
- BPC-157A peptide derived from a protective protein in your stomach.
- Thymosin Beta-4The full-length version of the protein TB-500 is cut from.
- How it works
- BPC-157Synthetic pentadecapeptide derived from a protein in human gastric juice. In animal studies it promotes angiogenesis, speeds tendon, ligament and muscle healing, modulates dopamine and serotonin systems, and protects the gut lining.
- Thymosin Beta-4Full-length Thymosin Beta-4 (as opposed to the TB-500 fragment). In cell and animal studies it promotes tissue repair, angiogenesis and cell survival. Regulates actin dynamics and plays a role in embryonic development and wound healing.
- Commonly reported
- BPC-157Faster recovery from tendon and ligament injuries, and a calmer gut. It's one of the most widely used peptides in the community; the human studies so far are three small uncontrolled pilots.
- Thymosin Beta-4Less nagging joint and soft-tissue pain and stiffness over a few weeks, and sometimes tiredness for a day after injecting. Its human trials are small eye-drop and skin-gel studies; injected use for injuries hasn't been tested in people.
- Studied range
- BPC-157Research range: 200–500 mcg. Studied in research — not a recommendation.
- Thymosin Beta-4Research range: 2–2.5 mg. Studied in research — not a recommendation.
- How often
- BPC-157Once or twice daily
- Thymosin Beta-4Weekly
- Half-life
- BPC-157~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes)
- Thymosin Beta-4~0.5–2 hours (given IV to healthy volunteers)
- Route
- BPC-157SubQ injection, IM injection, Oral (less studied)
- Thymosin Beta-4SubQ injection, IM injection
- Typical run
- BPC-157Typically 4–12 weeks. Many run until injury resolves then stop. Some run indefinitely at lower doses. Opinions vary widely.
- Thymosin Beta-4Shorter cycles than TB-500 typical — 4–6 weeks. Less community data than TB-500 fragment.
- Evidence
- BPC-157Emerging: primarily preclinical / limited human data
- Thymosin Beta-4Emerging: primarily preclinical / limited human data
- Common side effects
- BPC-157Nausea (rare), injection site irritation, vivid dreams, dizziness
- Thymosin Beta-4Injection site reaction, fatigue, headache
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
BPC-157
- Day 1–7 Week one: early hints, for some
- Day 7–14 Pain often starts to ease
- Day 14–21 Pain often eases by week three
- Day 21–28 Many report a calmer gut
- Day 28–42 The slower part of repair
- Day 42–56 Six weeks in: taking stock
- Day 84+ Past week 12, the data runs thin
Thymosin Beta-4
- Day 1–14 The full protein, not the fragment
- Day 14–28 Weeks 2 to 4: how the injury responds
Together or one or the other
BPC-157 and Thymosin Beta-4 are a common stack: Thymosin Beta-4 lists BPC-157 among its common stacks.
Community · Thymosin Beta-4
Full Tβ4 + BPC-157: local plus body-wide
BPC-157 works on local repair at the injury site, while full thymosin beta-4 helps repair cells move in from further afield. Commonly reported: faster recovery from stubborn soft-tissue injuries.
Questions people ask
How long do BPC-157 and Thymosin Beta-4 last?
The half-life of BPC-157 is ~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes). The half-life of Thymosin Beta-4 is ~0.5–2 hours (given IV to healthy volunteers).
How often are BPC-157 and Thymosin Beta-4 taken?
BPC-157: once or twice daily. Routes: SubQ injection, IM injection, oral (less studied). Thymosin Beta-4: weekly. Routes: SubQ injection, IM injection.
How are BPC-157 and Thymosin Beta-4 dosed in research?
The research range for BPC-157 is 200–500 mcg. The research range for Thymosin Beta-4 is 2–2.5 mg. Studied in research — not a recommendation.
What are the common side effects of BPC-157 and Thymosin Beta-4?
For BPC-157, the library lists: nausea (rare), injection site irritation, vivid dreams, dizziness. For Thymosin Beta-4: injection site reaction, fatigue, headache.
Are BPC-157 and Thymosin Beta-4 taken together?
BPC-157 and Thymosin Beta-4 are a common stack: Thymosin Beta-4 lists BPC-157 among its common stacks. BPC-157 works on local repair at the injury site, while full thymosin beta-4 helps repair cells move in from further afield. Commonly reported: faster recovery from stubborn soft-tissue injuries.